About Ankyrin repeat domain-containing protein 65
Ankyrin repeat domain-containing protein 65 (ANKRD65) is a protein
from Homo sapiens identified by UniProt accession
E5RJM6, 399 residues long.
MolForge cross-references it against 0 known binders and
11 disease associations.
Target properties
| Protein name | Ankyrin repeat domain-containing protein 65 |
| UniProt accession | E5RJM6 |
| Gene | ANKRD65 |
| Organism | Homo sapiens |
| Length | 399 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (11)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.32
- diastolic blood pressure · score 0.17
- refractive error measurement · score 0.11
- systolic blood pressure · score 0.05
- Drugs affecting bone structure and mineralization use measurement · score 0.04
- von Willebrand factor measurement · score 0.03
- eosinophil count · score 0.03
- colorectal cancer · score 0.01
- prostate carcinoma · score 0.01
- calf circumference measurement · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-E5RJM6-F1 | alphafold | PREDICTED | 85.40 | — |
Amino-acid sequence (399 residues)
MDSQRPEPRE EEEEEQELRW MELDSEEALG TRTEGPSVVQ GWGHLLQAVW RGPAGLVTQL LRQGASVEER DHAGRTPLHL AVLRGHAPLV RLLLQRGAPV GAVDRAGRTA LHEAAWHGHS RVAELLLQRG ASAAARSGTG LTPLHWAAAL GHTLLAARLL EAPGPGPAAA EAEDARGWTA AHWAAAGGRL AVLELLAAGG AGLDGALLVA AAAGRGAALR FLLARGARVD ARDGAGATAL GLAAALGRSQ DIEVLLGHGA DPGIRDRHGR SALHRAAARG HLLAVQLLVT QGAEVDARDT LGLTPLHHAS REGHVEVAGC LLDRGAQVDA TGWLRKTPLH LAAERGHGPT VGLLLSRGAS PTLRTQWAEV AQMPEGDLPQ ALPELGGGEK ECEGIESTG
Explore Ankyrin repeat domain-containing protein 65 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets